|Property||Resources - Mining|
|Resources - Oil & Gas||Technology|
|UK Commercial Property Trust||F&C Managed Portfolio Trust|
|Custodian REIT||Target Healthcare REIT|
|Blancco Technology Group||Collplant Holdings|
O2Micro International is a fabless semiconductor supplier of analog/mixed-signal ICs for LED lighting, battery and power management applications. It is based in California's Silicon Valley, incorporated in the Cayman Islands, and its ADSs trade on NASDAQ.
Ocean Capital comprises a group of companies engaged in the sourcing, structuring, provision, and management of long-term lending solutions to corporate borrowers, in specific industries, predominantly in Europe. Ocean Capital Associates LLP is the London-based investment management limited-liability partnership of Ocean Capital, majority owned by its investment team, and regulated by the FCA.
OceanaGold is an established gold producer listed on three exchanges (ASX, TSX and NZX) with exploration, development and production assets in New Zealand (Macraes, Frasers, Reefton) and the Philippines (Didipio), with total NI 43-101 resources of 10.3Moz gold and 363kt copper.
Omega Insurance Holdings is domiciled in Bermuda and listed on the London Stock Exchange. It is an international insurer/reinsurer with a focus on short-tail, property-oriented classes.
OMG is a group of technology companies that provide image-understanding products and services for the entertainment, defence, life science, engineering and highways maintenance industries. It has recently launched its first consumer product, Autographer, the world's first intelligent wearable camera.
OncoGenex is a drug discovery and development company creating novel treatments for various cancers. Its leading products are antisense therapies which promote the programmed cell death of tumour cells.
OncoMed is a clinical-stage biotechnology company engaged in developing monoclonal antibodies and other agents that target the biologic pathways critical to tumour-initiating cells, also known as cancer stem cells (CSC). It has five candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18). OncoMed has collaborations with Celgene, Bayer and GSK.
Oncothyreon is developing L-BLP25, a Phase III cancer vaccine for non-small cell lung cancer (NSCLC) targeting MUC1 antigen; ONT-10, a follow-on vaccine candidate; PX-866, a pan-isoform PI-3K inhibitor in multiple Phase II studies; and ARRY-380, a small-molecule selective HER2 inhibitor.
Onyx is a biopharmaceutical company focused on developing and commercialising drugs for cancer and inflammatory diseases. Its approved drugs are Nexavar and Kyprolis. Drugs under development include oprozomib (Phase II, cancer) and ONX 0914 (pre-IND, ID). Onyx is located in South San Francisco, CA.
OPG is an independent power producer based in the Indian state of Tamil Nadu, with 112MW of capacity, which is set to increase to 742MW by FY15. The group captive model enables OPG to sell to industrial (minority) shareholders or state customers and is able to use either domestic or imported coal.
Optos uses a leasing model for c 3,700 wide-field laser retinal imaging systems used by optometrists. Instruments are leased for a fixed amount ($2,000 per month) and 53% generate additional pay-per-use (PPU) revenues (c $20/use) over a typical 36-month contract. Vendor finance is being run down. Finance leasing is now used for c 100 units.
Orbis Gold is an Australian junior exploring for high grade gold deposits in Burkina Faso, where it has a total resource of approximately 2.5Moz. The company is looking to partner early stage IOCG and copper exploration interests in Queensland, Australia.
Orexigen is a biopharmaceutical company focusing on obesity treatments. It will sell its sole product, Contrave, through its own salesforce in the US after taking back the rights from partner, Takeda. Contrave was launched in the US in Oct 2014 and approved in the EU in March 2015 under the trade name Mysimba.
Orosur Mining owns (100%) and operates its San Gregorio gold mine in Uruguay. It explores for gold close to San Gregorio and in Chile at the Anillo gold property. It owns 100% of the highly prospective, high-grade Anzá gold property in Colombia.
Oryzon is a Spanish biotechnology company focused on developing novel epigenetic compounds. Lead compound ORY-1001 is partnered with Roche and is undergoing a Phase I/IIa study for acute leukaemia. ORY-2001 has potential for Alzheimer’s disease and has been approved to enter Phase I.
Otto Energy is an Australia-listed E&P with exploration licences in the Philippines, Tanzania and Alaska. It has fully divested its producing Galoc field in the Philippines. Focus is now on Tanzania and Alaska.
Outsourcery is a UK-based cloud services provider. From its proprietary O-Cloud platform, the company delivers cloud-based ICT applications and solutions on a subscription basis via a network of partners.
Oxford BioMedica is a leader in gene and cell therapy. The lentivector technology is wide ranging, covering in vivo and ex vivo vector products. The technology underpins the proprietary clinical development pipeline in addition to third party manufacturing contracts which add validation to the platform.
Oakley Capital Investments invests in a portfolio of private mid-market UK and European companies. The manager aims to achieve superior returns by purchasing businesses at depressed valuations and making strategic and operational improvements.
Ocean Wilsons Holdings is a holding company with a controlling 58.25% stake in Wilson Sons, a listed Brazilian maritime and logistics business. It also has an investment division (OWIL), with a diversified portfolio of equities, bonds and other assets.
Oceania Natural is a producer, distributor and reseller of natural food and supplement products sourced from New Zealand and the Pacific Islands, sold predominantly into the People’s Republic of China. Its chief products are manuka honey and related products, Noni juice and dietary supplements.
Omega is a UK-based company focused on developing and marketing in-vitro diagnostic products in infectious and autoimmune diseases and for food intolerance. Intolerance tests account for over 40% of revenues.
OmniVision Technologies is a fabless semiconductor company that is a leading supplier of CMOS image sensors. It is based in California's Silicon Valley.
Oncolytics Biotech is a Canadian company focused on developing Reolysin, a pharmaceutical formulation of the oncolytic reovirus, for the treatment of a wide variety of human cancers (Phase III trial in head and neck cancer).
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule drug candidates to treat cancer. Its lead drug candidate, rigosertib, is partnered with Baxter (Europe) and SymBio (Japan/Korea).
Onxeo is focused on orphan cancer and has three late-stage orphan oncology assets it could commercialise alone in Europe (Livatag, Beleodaq and Validive). Royalty-earning Beleodaq (belinostat) is launched in the US, along with two non-core, partnered, specialty products.
Opexa is developing personalized T-cell immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases such as neuromyelitis optica (NMO). Lead candidate Tcelna is in Phase IIb studies for secondary progressive MS (SPMS), with data expected in H216.
OPMEDIC Group is a Canadian provider of assisted reproductive technology (ART) services (~90% of revenue) and surgical and endoscopic services (~10%). Nearly all its facilities are located in Quebec, where in vitro-fertilisation (IVF) services are funded by the provincial government.
Oracle Coalfields plc is a coal exploration and development company. Block VI, its main project, has total measured resources (JORC) of 1.4bn tonnes of lignite coal and is located in southern Pakistan’s Thar coalfield.
Orbite Aluminae has developed a process to extract alumina from aluminous clays to produce smelter grade alumina (SGA), high purity alumina (HPA) and valuable byproducts. Commercial HPA production is expected at Orbite's Cap-Chat facility during 2013. Orbite owns 100% mining rights on an aluminous clay deposit at Grande-VallÃ©e in Quebec.
Orexo is a Swedish speciality pharma company with expertise in drug delivery/reformulation technologies in particular sublingual formulations, and a US commercial infrastructure for opioid dependence therapy, Zubsolv.
Ormonde Mining is an AIM- and ESM-listed mineral development and exploration company with properties in western Spain. It is advancing a low-cost tungsten operation at Barruecopardo slated for first production in 2013.
OEG is focused on thermal coal activities in Kalimantan, Indonesia. It is pursuing a vertical integration strategy and has acquired exclusive port allocation slots that are being used to generate additional revenue through loading other producers' coal.
Oshkosh Corporation is a leading manufacturer and marketer of access equipment, speciality vehicles and truck bodies for the primary markets of defence, concrete placement, refuse hauling, access equipment and fire and emergency services. Defence accounts for 48% of sales.
OTC Markets Group operates the OTCQX, OTCQB and Pink financial markets for c 10,000 US and global securities. Its trading system, OTC Link ATS, is operated by OTC Link LLC, a member of FINRA and is an SEC regulated Alternative Trading System.
Outotec is the global leader in minerals and metals processing technology. It supplies machinery and related technology to refine ferrous and non-ferrous materials, from ore to pure metal. 80% of sales constitute machinery, with the remainder made up of services.
OvaScience is a US-based life sciences company focused on developing and commercialising new treatments for infertility. The company's products (AUGMENT, OvaTure) are based on the discovery of egg precursor cells in ovaries. Both products are designed to improve in vitro fertilisation.